Primary Outcome Measures:
- Proportion of patients who experience specified events [ Time Frame: 10 years ] [ Designated as safety issue: No ]
To collect and evaluate safety and effectiveness data specific to the use of eculizumab in aHUS patients.
- Time to first and subsequent occurrence of specified events. [ Time Frame: 10 years ] [ Designated as safety issue: No ]
To assess the long term manifestations of thrombotic microangiopathy (TMA) complications of aHUS as well as other clinical outcomes, including morbidity and mortality in aHUS patients, receiving eculizumab treatment or other disease management approaches
The study will capture post-marketing safety data on patients treated with eculizumab. Additionally, the study will collect information on the progression of disease in all patients.